Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenqi Baofei Fang is a Traditional Chinese Medicine (TCM) herbal formula primarily utilized for the treatment of chronic respiratory conditions, including chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The formula is designed based on the TCM principles of tonifying Qi and nourishing the Lung, typically incorporating key botanical ingredients such as *Astragalus membranaceus* (Huang Qi), *Panax ginseng* (Ren Shen), *Ophiopogon japonicus* (Mai Dong), and *Schisandra chinensis* (Wu Wei Zi). Mechanistically, it is reported to exert anti-inflammatory and immunomodulatory effects by inhibiting the expression of pro-inflammatory cytokines like TNF-alpha and IL-6, thereby reducing airway remodeling and improving pulmonary function. Clinical research, particularly in China, has focused on its efficacy in stabilizing COPD patients and enhancing their quality of life.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenqi Baofei Fang.